What is the appropriate Paxlovid (nirmatrelvir/ritonavir) dosing based on a patient’s estimated glomerular filtration rate (eGFR)?

Paxlovid Dosing Based on eGFR

For patients with eGFR ≥60 mL/min, use the standard dose of nirmatrelvir 300 mg/ritonavir 100 mg twice daily for 5 days; for eGFR 30-59 mL/min, reduce to nirmatrelvir 150 mg/ritonavir 100 mg twice daily for 5 days; and avoid Paxlovid in patients with eGFR <30 mL/min unless newer evidence supports its use. 1

Standard Dosing (Normal to Mild Renal Impairment)

• eGFR ≥60 mL/min: No dose adjustment needed
  • Nirmatrelvir 300 mg (two 150 mg tablets) + ritonavir 100 mg (one tablet)
  • Administer twice daily for 5 days
  • Initiate within 5 days of symptom onset 1

Dose Reduction for Moderate Renal Impairment

• eGFR 30-59 mL/min: Reduce nirmatrelvir dose by 50%
  • Nirmatrelvir 150 mg (one 150 mg tablet) + ritonavir 100 mg (one tablet)
  • Administer twice daily for 5 days
  • Note that ritonavir dose remains unchanged at 100 mg 1
  • WHO guidelines support this dose reduction approach 2

Severe Renal Impairment

• eGFR <30 mL/min: FDA labeling states Paxlovid is not recommended until more data are available, as the appropriate dosage has not been determined 1

Emerging Evidence for Severe Renal Impairment

Recent research challenges the FDA's conservative stance:

• A 2026 phase 1 study (EPIC-SRI) evaluated nirmatrelvir/ritonavir 300/100 mg on Day 1, followed by 150/100 mg once daily (not twice daily) on Days 2-5 in patients with severe renal impairment, including those on hemodialysis. This regimen was well-tolerated with no treatment-related adverse events and achieved adequate drug exposure 3

• Real-world data from Veterans Health Administration showed that off-label use in patients with eGFR 15-30 mL/min was associated with reduced respiratory failure and pneumonia without increased cardiovascular or liver injury risks, though acute kidney injury risk was higher compared to molnupiravir 4

• PBPK modeling suggests that for severe renal impairment, a loading dose of 300/100 mg followed by 150/100 mg twice daily may be appropriate 5

Critical Implementation Points

Timing: Start treatment as soon as possible after COVID-19 diagnosis and within 5 days of symptom onset, even if symptoms are mild 1

Co-administration requirement: Nirmatrelvir MUST be given with ritonavir. Failure to co-administer results in insufficient nirmatrelvir levels and therapeutic failure 1

Drug interactions: Ritonavir is a potent CYP3A4 inhibitor causing significant drug-drug interactions. Review all concomitant medications before prescribing, as some drugs are contraindicated and others require dose adjustment 2, 1

Monitoring in renal impairment: In kidney transplant recipients and patients with advanced kidney disease, close monitoring of renal function is warranted, though studies show generally stable or improved creatinine levels during treatment 6

Common Pitfalls to Avoid

• Don't prescribe nirmatrelvir alone: The co-packaged formulation ensures proper ritonavir boosting
• Don't use standard dosing in moderate renal impairment: This leads to drug accumulation and potential toxicity
• Don't forget to check eGFR: Calculate it before prescribing, as renal function determines the appropriate dose pack
• Don't overlook drug interactions: The ritonavir component causes more interaction concerns than nirmatrelvir itself